Quxin Biopharmaceutical

Quxin Biopharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on the discovery and development of targeted protein degradation (TPD) therapies. The company specializes in "molecular glue" degraders, an innovative modality designed to eliminate disease-causing proteins that are otherwise difficult to target with traditional small molecules. Its lead candidate, QX-001, is a potent molecular glue degrader targeting GSPT1 and is currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors. Quxin leverages a proprietary platform to identify novel glue molecules and is supported by top-tier investors such as Sequoia China and 5Y Capital. The company's mission is to provide transformative treatments for patients with cancer and other unmet medical needs through its expertise in protein homeostasis.